In the wake of the COVID-19 global pandemic, which started when the virus SARS-CoV-2 jumped from animals into humans, we ask an important question why are infections acquired from animals so dangerous to human health?
While it is not yet clear which animals were the source of the new coronavirus was it bats? Was it pangolins? Was it both? scientists are sure that SARS-CoV-2, the virus that causes COVID-19, originated from animals.
The numbers of confirmed COVID-19 cases across the world are staggering. According to Johns Hopkins University, more than 730,000 people have contracted the virus and 34,000 people have died.
But zoonotic diseases that is, diseases acquired from animals were affecting vast numbers of people across the world before COVID-19 took center stage.
Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.
An international report from 2012, for example, informed that a total of 56 such diseases were responsible for 2.5 billion cases of illness and 2.7 million deaths across the globe each year. These illnesses included rabies, toxoplasmosis, Q fever, Dengue fever, avian influenza, Ebola, and anthrax.
Furthermore, respiratory, flu-like diseases acquired from animals wreaked havoc in the past century. The Spanish flu caused 50 million deaths in 1918, and the Hong Kong flu caused 700,000 deaths in 1968.
So, why are diseases that humans acquire from animals so dangerous? Part of it is due to our immune system. Part of it is natural selection. The specific animal that transmits the virus may also play a role.
Below, we explore some of these factors and how they intertwine.
One reason viruses from animals are so dangerous to humans is that people have no means to deal with them. Our immune system was never introduced to these novel viruses, so it doesnt know how to respond to the uninvited guest.
Researchers explain that most of the viruses that enter the human body are successfully destroyed by the immune system or pass through our gastrointestinal system. However, now and then, an animal virus manages to replicate within a human host.
The moment where the animal virus replicates within the body of the first human is crucial. At this critical point, the virus can mutate and evolve under the selective constraints of the human body for the first time, adapting and improving itself for replication in this new host.
As this occurs, the human immune system must retaliate. It needs to catch up with the virus evolution and create an immune response. The human body has never been confronted with this threat before, and therefore, has no pre-existing immunity in its arsenal so it must devise one fast.
But, this defense part of the adaptive immune system takes days or longer to activate. In the meantime, the virus may have already evolved to replicate faster or even escape the immune systems retaliation.
In other words, the animal virus and the human immune system have entered an arms race and like with any arms race, one of the two competitors could win, or both competitors could reach a stalemate.
Medical News Today spoke to Christopher Coleman, assistant professor of Infection Immunology at the University of Nottingham in the United Kingdom, about animal viruses, human hosts, and the role of evolution and natural selection.
[T]he general assumption, he explained, is that as viruses evolve to a host, they become less dangerous to that host (they want to ensure their own transmission so dont want to rapidly kill the host before they get a chance [to replicate]).
This is by no means [always] true, but a virus that adapts to humans might be less dangerous in the long term because the evolutionary arms race between virus and host has reached a sort of stalemate where neither is perfectly happy, but neither is killed off.
Christopher Coleman
Furthermore, a virus that fully adapts to an animal host may be completely harmless to humans, Coleman continued.
The scientist whose main research focuses on highly pathogenic human coronaviruses gave examples of aggressive animal viruses within the coronavirus family. These include the infectious bronchitis virus of chickens, feline infectious peritonitis virus in cats, or transmissible gastroenteritis virus, which is near 100% fatal in piglets.
None of these [viruses] are known to infect or cause any disease in humans, Coleman said.
On the other hand, a virus that evolves in animals but also has an ability to infect humans may be more deadly if and or when it infects humans.
This may be especially true when the animals immune systems are very different from those of humans, or when the animals have special defense mechanisms that humans lack.
For instance, the fact that very harmful viruses such as SARS, MERS, and Ebola have all originated in bats begs the question what do bats have that we dont?
How can bats fly around carrying viruses that, in some cases, are extremely deadly to humans (such as Ebola), but that do not seem to harm these creatures in the slightest?
A new study, led by Cara Brook, a postdoctoral Miller Fellow at the University of California Berkeley, asked this very question. The research shows how bats unique immune capabilities enable them to carry and maintain a high viral load without getting sick themselves.
[S]ome bats, explain Brook and colleagues in their paper, have an antiviral immune response called the interferon pathway perpetually switched on.
In most other mammals, having such a hyper-vigilant immune response would cause harmful inflammation. Bats, however, have adapted anti-inflammatory traits that protect them from such harm.
Cara Brook et al
This is all great news for bats, but what does it do for other mammals? Sadly, not much. The fact that bats have such good defenses means that the virus has all the encouragement it needs to replicate more quickly.
The bats unique immune capabilities eventually make the viruses stronger. It is like training with an outstanding competitor and getting stronger as a result.
Brook and her team carried out experiments using cell lines from two species of bats. The results showed that in both bat species, the strongest antiviral responses were countered by the virus spreading more quickly from cell to cell.
This suggests that bat immune defenses may drive the evolution of faster transmitting viruses, and while bats are well protected from the harmful effects of their own prolific viruses, other creatures, including humans, are not.
Cara Brook et al.
Our immune system would generate widespread inflammation if attempting this same antiviral strategy. But bats appear uniquely suited to avoiding the threat of immunopathology, says Brook.
In the case of the new coronavirus, multiple theories are circulating about the specific animal that passed on SARS-CoV-2 to humans. Scientists have implicated pangolins or even snakes as possible carriers.
Pinning down specific mammals is vital because the animal can offer insights into the genetic structure of the virus and ways to tackle it. However, it is essential not to discount the possibility that the new coronavirus might have several animal sources.
Commenting on the theory that humans contracted SARS-CoV-2 from pangolins, Coleman said: Its as good a theory as any [] This, of course, does not mean that pangolins are the only source it may be that there are other species.
For example, with the original SARS-CoV, civet cats were the most famous species involved, but there were other small mammals infected. Also, although dromedary camels are the source of MERS-CoV, there is strong evidence that other camelids can also be infected.
Regardless of which animals specifically gave humans the new coronavirus, it may be more important to ask, when and where did the virus mutate?
In a recent study, researchers led by Kristian Andersen, Ph.D., an associate professor of immunology and microbiology at the Scripps Research Institute in LaJolla, CA, used the available genomic data to determine whether the origin of the new coronavirus was natural or made by humans.
Having determined that the virus is the result of natural evolution, the authors explain that depending on whether the virus adapted in its current form in animals or humans, the course of the new coronavirus pandemic could be quite different.
[I]f SARS-CoV-2 pre-adapted in another animal species, write the authors in the journal Nature, then there is the risk of future re-emergence events.
In other words, if the virus evolved to its current state in animals, then animals would continue to pass it amongst each other, and the virus could jump back into humans at any point.
Furthermore, the researchers suggest that this scenario would explain why the virus spread so quickly. Seeing that it had already developed its pathogenic traits in animals, SARS-CoV-2 was already trained to spread and replicate quickly once it entered its first human host.
In contrast, write Andersen and colleagues, if the adaptive process occurred in humans, then even if repeated [animal-to-human] transfers occur, they are unlikely to take off without the same series of mutations, therefore minimizing the chances of another outbreak.
For now, it is impossible to know which of the two scenarios is more likely. Only time, and more research, will tell.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.
More:
Zoonotic diseases: Why are infections from animals so dangerous to hu - Medical News Today
- As dengue spreads, researchers discover a clue to fighting the virus - La Jolla Institute for Immunology - February 25th, 2025 [February 25th, 2025]
- Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business... - February 25th, 2025 [February 25th, 2025]
- PhD candidate Jesse Lehman receives Kirschstein Award to study immunology - UMass Medical School - February 25th, 2025 [February 25th, 2025]
- Cross-priming in cancer immunology and immunotherapy - Nature.com - February 3rd, 2025 [February 3rd, 2025]
- Sanofi Happy To Spend To Hit Immunology Top Spot - News & Insights - February 3rd, 2025 [February 3rd, 2025]
- The Converging Therapeutic Landscape of Oncology and Immunology: Accelerating Innovation in Biotech - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- Immunology - The Scientist - January 23rd, 2025 [January 23rd, 2025]
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]